Authors: Jansen¹; Van Oene,²

Source: Alimentary Pharmacology & Therapeutics, Volume 13, Number 12, December 1999 , pp. 1611-1620(10)

Publisher: Wiley-Blackwell

Abstract:

Background: 

In the treatment of reflux oesophagitis, H₂-receptor antagonists are still widely used in spite of the apparent higher efficacy of proton pump inhibitors. In an attempt to compensate for the lower efficacy, H₂-receptor antagonists are now increasingly being used at a higher dose. Objective: 

To assess whether or not standard-dose lansoprazole (30 mg o.d.) is more effective than high-dose ranitidine (300 mg b.d.) in moderately severe reflux oesophagitis (grades II-III). Methods: 

Lansoprazole or ranitidine was given to 133 patients for 4-8 weeks in a double-blind, randomized, parallel group, multicentre trial. Results: 

The percentage of patients with endoscopically-verified healing was significantly higher on lansoprazole than on ranitidine both after 4 weeks (79% vs. 42%) and 8 weeks (91% vs. 66%), though smoking had a negative impact on oesophagitis healing with lansoprazole. Heartburn, retrosternal pain and belching improved significantly better with lansoprazole than with ranitidine, as did the patient-rated overall symptom severity. Relief of heartburn appeared somewhat faster with ranitidine, but was more pronounced with lansoprazole. The number of patients with adverse events was similar in both treatment groups. Conclusion: 

Standard-dose lansoprazole is better than high-dose ranitidine in moderately severe reflux oesophagitis.

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1365-2036.1999.00656.x

Affiliations: 1: Department of Gastroenterology, Academic Hospital Nijmegen St. Radboud, Nijmegen, the Netherlands, 2: Department of Clinical Research, Janssen-Cilag BV, Tilburg, the Netherlands

Publication date: 1999-12-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pathology ,  Pharmacology ,  Surgery ,  Therapeutics & Alternative Medicine
• By this author: Jansen ;  Van Oene,

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers